Cytek Investor Presentation Deck

Note: Fiscal Quarter Non-GAAP Adjusted EBITDA ($ in thousands) Non-GAAP Adjusted EBITDA Reconciliation ($ in thousands) Net Income Adjustments Depreciation and Amortiza Provision for (Benefits from Interest Income Interest Expense Foreign currency exchange Litigation Settlement Loss on Lease Exit Cost Acqisition Related Expenses Stock-Based Compensatior Adjusted EBITDA Revenue Adjusted EBITDA % of Reven FY20A 19,411 578 (4,982) (110) 333 (463) 611 15,379 92,839 17% FY21A 1Q2020 2Q2020 3Q2020 4Q2020 3,027 (839) 8,111 5,600 6,539 1,241 2,921 (49) 1,741 1,481 105 198 (86) 0 104 161 (7,914) (15) 1 (79) 6,586 105 109 17,525 (411) 373 127,950 17,988 19,137 14% -2% 2% 179 387 (3) 2 (137) 125 7,091 25,095 28% 133 2,348 (5) 330 (350) 271 8,327 30,619 27% 1Q2021 2Q2021 101 2,671 169 50 (10) 375 663 456 1,804 24,272 7% 194 597 (9) 433 135 667 4,688 30,408 15% 3Q2021 1,420 194 655 (12) 442 388 4Q2021 (1,165) 685 1,619 (19) 492 295 1Q2022 2Q2022 3Q2022 (2,158) (701) 1,626 1,470 (1,144) (18) 590 422 347 229 2,455 3,837 3,008 5,542 5,491 34,376 38,893 35,064 2,998 16% 14% 9% 1,636 (700) (391) 647 331 3,934 4,756 40,159 12% 1,452 225 (1,584) 649 570 4,359 7,296 40,477 17% CYTEK TRANSCEND THE CONVENTIONAL 20

View entire presentation